Icure Pharmaceutical Incorporation (175250)

KOSDAQ · 2,170 KRW · As of Aug 26, 2026 close

Mkt Cap

81.5B

Rev (2025)

83.4B

Op Inc (2025)

-12.0B

Net Inc (2025)

-34.5B

PBR

3.33

52W

2K~2K

Icure Pharmaceutical Incorporation operates in the Chemicals sector.

Legal name: Icure Pharmaceutical Incorporation

In fiscal year 2025, Icure Pharmaceutical Incorporation (175250) reported revenue of 83.4 billion KRW, up 20.5% from 69.2 billion KRW a year earlier.

Operating profit was -12.0 billion KRW and net income was -34.5 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 81.5 billion KRW, with a P/B of 3.33.

These figures can be verified in the DART filing (receipt no. 20260507000634).

Year	Rev	Op Inc	Net Inc
2025	83.4B	-12.0B	-34.5B
2024	69.2B	-17.2B	25M
2023	56.8B	-22.7B	-32.3B

5 applicable out of 8 items

[기재정정]주요사항보고서(유상증자결정)

Semi-Annual Report (2026.06)

기타시장안내 (개선계획 이행내역서 제출)

Checks

5 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: 2 administrative designation criteria met. [source]

Audit Opinion: Audit opinion: Unqualified (clean).

Convertible Bonds: Convertible bonds outstanding with 0.1% potential dilution.

Capital Increase: 1 capital-increase filing(s) in the last 180 days. [source]

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: 5 embezzlement/litigation filing(s) in the last 180 days. [source]

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: 1 market action(s) (trading halt, delisting, etc.) recorded. [source]

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.